Keros Therapeutics (KROS) Competitors $55.92 +2.08 (+3.86%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KROS vs. SRRK, DRNA, SRRA, YMAB, AMRN, ITCI, ROIV, ASND, LEGN, and ELANShould you be buying Keros Therapeutics stock or one of its competitors? The main competitors of Keros Therapeutics include Scholar Rock (SRRK), Dicerna Pharmaceuticals (DRNA), Sierra Oncology (SRRA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Elanco Animal Health (ELAN). These companies are all part of the "medical" sector. Keros Therapeutics vs. Scholar Rock Dicerna Pharmaceuticals Sierra Oncology Y-mAbs Therapeutics Amarin Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Legend Biotech Elanco Animal Health Scholar Rock (NASDAQ:SRRK) and Keros Therapeutics (NASDAQ:KROS) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Do institutionals & insiders hold more shares of SRRK or KROS? 91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 19.2% of Scholar Rock shares are held by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in SRRK or KROS? Scholar Rock received 110 more outperform votes than Keros Therapeutics when rated by MarketBeat users. However, 72.22% of users gave Keros Therapeutics an outperform vote while only 65.32% of users gave Scholar Rock an outperform vote. CompanyUnderperformOutperformScholar RockOutperform Votes16265.32% Underperform Votes8634.68% Keros TherapeuticsOutperform Votes5272.22% Underperform Votes2027.78% Do analysts rate SRRK or KROS? Scholar Rock currently has a consensus price target of $34.00, indicating a potential upside of 13.64%. Keros Therapeutics has a consensus price target of $88.89, indicating a potential upside of 58.96%. Given Keros Therapeutics' higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than Scholar Rock.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Keros Therapeutics 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, SRRK or KROS? Keros Therapeutics has lower revenue, but higher earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScholar Rock$33.19M84.39-$165.79M-$2.35-12.73Keros Therapeutics$651K3,479.50-$152.99M-$5.21-10.73 Does the media refer more to SRRK or KROS? In the previous week, Scholar Rock had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 6 mentions for Scholar Rock and 5 mentions for Keros Therapeutics. Scholar Rock's average media sentiment score of 0.18 beat Keros Therapeutics' score of -0.28 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is SRRK or KROS more profitable? Scholar Rock has a net margin of 0.00% compared to Keros Therapeutics' net margin of -27,890.94%. Keros Therapeutics' return on equity of -41.74% beat Scholar Rock's return on equity.Company Net Margins Return on Equity Return on Assets Scholar RockN/A -145.60% -91.83% Keros Therapeutics -27,890.94%-41.74%-38.42% Which has more volatility & risk, SRRK or KROS? Scholar Rock has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. SummaryKeros Therapeutics beats Scholar Rock on 10 of the 19 factors compared between the two stocks. Ad Brownstone ResearchShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Click here for full details. Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KROS vs. The Competition Export to ExcelMetricKeros TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.18B$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-10.7310.35102.4617.58Price / Sales3,479.50362.011,234.85158.43Price / CashN/A52.6040.4736.33Price / Book4.2510.377.096.50Net Income-$152.99M$153.60M$119.65M$226.22M7 Day Performance-1.24%3.92%2.06%3.76%1 Month Performance-3.57%-6.78%-2.46%4.63%1 Year Performance84.19%33.23%33.95%29.20% Keros Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KROSKeros Therapeutics3.5943 of 5 stars$55.92+3.9%$88.89+59.0%+84.2%$2.18B$651,000.00-10.73100Analyst ForecastSRRKScholar Rock4.2047 of 5 stars$27.92+4.7%$34.00+21.8%+164.1%$2.61B$33.19M-11.70140DRNADicerna PharmaceuticalsN/A$38.22flatN/AN/A$2.99B$164.31M-23.45302SRRASierra OncologyN/A$54.99flatN/AN/A$1.34B$300,000.00-8.12109YMABY-mAbs Therapeutics3.14 of 5 stars$10.19+0.9%$21.38+109.8%+91.0%$456.41M$84.82M0.00150AMRNAmarin0.0968 of 5 stars$0.56+5.7%N/A-29.4%$227.92M$306.91M-5.83360ITCIIntra-Cellular Therapies4.4537 of 5 stars$85.61+0.2%$97.23+13.6%+44.6%$9.08B$612.78M-98.22560Positive NewsROIVRoivant Sciences3.337 of 5 stars$12.19+3.1%$17.93+47.1%+39.2%$9.01B$124.79M2.10860Insider TradeASNDAscendis Pharma A/S2.9978 of 5 stars$127.81+4.2%$191.77+50.0%+39.6%$7.75B$327.43M-15.22640Analyst UpgradeLEGNLegend Biotech1.4505 of 5 stars$40.26+1.3%$81.46+102.3%-31.9%$7.34B$285.14M-41.841,800ELANElanco Animal Health3.8657 of 5 stars$13.32-0.6%$17.14+28.7%+11.9%$6.58B$4.42B33.519,300 Related Companies and Tools Related Companies Scholar Rock Alternatives Dicerna Pharmaceuticals Alternatives Sierra Oncology Alternatives Y-mAbs Therapeutics Alternatives Amarin Alternatives Intra-Cellular Therapies Alternatives Roivant Sciences Alternatives Ascendis Pharma A/S Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KROS) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
